ROCKVILLE, Md. - GlycoMimetics, Inc. (NASDAQ: NASDAQ:GLYC) has announced it will acquire Crescent Biopharma, Inc., a private biotechnology company focused on developing oncology therapeutics for solid tumors. The transaction is expected to be finalized in the second quarter of 2025, with GlycoMimetics planning to adopt the Crescent Biopharma name post-merger.
The merger is supported by a $200 million financing commitment from a syndicate of investors, including Fairmount, Venrock Healthcare Capital Partners, and others. This funding is anticipated to sustain the combined entity's operations through 2027, enabling the advancement of Crescent's lead program, CR-001, and other pipeline projects.
CR-001, a tetravalent PD-1 x VEGF bispecific antibody, is designed to enhance the efficacy of immuno-oncology treatments. Crescent anticipates preliminary proof of concept data for CR-001 in the second half of 2026. Additionally, Crescent is developing two antibody-drug conjugates, CR-002 and CR-003, which utilize topoisomerase inhibitor payloads, a method that has shown improved efficacy and safety in previous studies.
The merger has received approval from the boards of both companies, with closing contingent upon stockholder approval and other customary conditions. Upon completion, GlycoMimetics stockholders are expected to own approximately 3.1% of the new company, with Crescent stockholders owning the remainder.
Jonathan Violin, interim CEO of Crescent and Venture Partner at Fairmount, expressed confidence in the lead program's potential, citing the precision engineering of CR-001 and its cooperative binding pharmacology. Harout Semerjian, CEO of GlycoMimetics, also conveyed optimism about the merger's prospects for advancing patient care.
The combined company will be led by Violin, with a board of directors that includes Peter Harwin from Fairmount. Crescent and GlycoMimetics will hold a conference call on Tuesday to discuss the merger details.
This strategic move aims to leverage recent breakthroughs in immuno-oncology and antibody-drug conjugates to bring next-generation therapies to patients with solid tumors. The companies also plan to explore potential paths forward for GlycoMimetics' late-stage clinical candidate, Uproleselan.
This article is based on a press release statement from GlycoMimetics, Inc.
InvestingPro Insights
As GlycoMimetics (NASDAQ: GLYC) prepares for its merger with Crescent Biopharma, investors should consider some key financial metrics and insights from InvestingPro. The company's market capitalization stands at a modest $10.85 million, reflecting its current position as a small-cap biopharmaceutical firm.
InvestingPro data reveals that GlycoMimetics holds more cash than debt on its balance sheet, which could be viewed positively in light of the upcoming merger and the need for financial stability during the transition. This aligns with the article's mention of the $200 million financing commitment, suggesting that the combined entity will have a strong financial foundation to support its operations through 2027.
However, investors should note that GlycoMimetics is quickly burning through cash, according to an InvestingPro Tip. This information is particularly relevant given the company's plans to advance Crescent's lead program and other pipeline projects, which typically require significant capital expenditure in the biopharmaceutical industry.
Another InvestingPro Tip indicates that analysts anticipate a sales decline in the current year for GlycoMimetics. This forecast may explain the company's strategic decision to merge with Crescent Biopharma, potentially seeking to bolster its product pipeline and future revenue prospects.
It's worth noting that InvestingPro offers 12 additional tips for GlycoMimetics, providing a more comprehensive analysis for investors interested in delving deeper into the company's financial health and market position.
The merger announcement comes at a time when GlycoMimetics' stock has experienced significant volatility. InvestingPro data shows a 6-month price total return of -89.15%, indicating substantial recent losses for shareholders. This context underscores the importance of the merger and the accompanying financing as potential catalysts for the company's future growth and value creation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.